Status:

COMPLETED

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

Lead Sponsor:

Sanofi

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

21+ years

Phase:

PHASE4

Brief Summary

Primary Objective: To evaluate the effect of prandial treatment adjustment, based on continuous blood glucose monitoring, on glucose control in type 2 diabetes patients who are not controlled by trea...

Detailed Description

The study duration for each patient is 24 weeks +/- 1 week broken down as follows: * Run-in phase: 8 weeks * Follow - up Period: 16 weeks The maximal possible time window during the study is +/- one...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Run-in period:
  • Type 2 diabetes
  • HbA1c≥ 8.5% (in a test of the last month)
  • Age above 21 years
  • Patients continuously treated with basal insulin or mixed insulin once daily for the last 6 months
  • Signed informed consent form
  • Patients who according to their physician are eligible to the study
  • Randomization:
  • HbA1c \> 7.5%
  • FPG \< 130 mg/dl
  • Exclusion criteria:
  • Type 1 diabetes
  • Patients continuously treated with short-acting insulin or mixed insulin more than once daily for 3 weeks during the last 6 months.
  • Pregnant or breastfeeding women.
  • Patients with allergy to insulin.
  • Patients with severe diseases characterized by recurrent hospitalizations, including: Severe renal insufficiency, severe cardiac insufficiency, active oncological disease or oncological disease requiring chemotherapy.
  • Patients with mobility difficulties and/or difficulties communicating with the investigator
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Exclusion

    Key Trial Info

    Start Date :

    December 1 2012

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2015

    Estimated Enrollment :

    219 Patients enrolled

    Trial Details

    Trial ID

    NCT01234597

    Start Date

    December 1 2012

    End Date

    April 1 2015

    Last Update

    July 13 2016

    Active Locations (11)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (11 locations)

    1

    Investigational Site Number 376003

    Beersheba, Israel

    2

    Investigational Site Number 376007

    Haifa, Israel

    3

    Investigational Site Number 376004

    Kfar Saba, Israel, 44281

    4

    Investigational Site Number 376012

    Lod, Israel